



**Clinical Edit Criteria**

Drug/Drug Class: **Niravam® Oral Disintegrating Tablets Clinical Edit**  
 Date: **September 7, 2005**  
 Prepared for: **MO HealthNet**  
 Prepared by: **ACS Heritage, Inc.**

**New Criteria**

**Revision of Existing Criteria**

**Executive Summary**

**Purpose:** Ensure appropriate utilization and control of Niravam® (alprazolam oral disintegrating tablets).

**Why was this Issue Selected:**

Niravam® is a branded drug product containing alprazolam and is designed to rapidly dissolve on the tongue, allowing patients to take the medication discreetly without water, anytime, anywhere. The product is approved for the treatment anxiety associated with depression and panic disorder with or without agoraphobia in adults. Niravam® is available in four strengths (0.25mg, 0.5mg, 1mg and 2mg). Generic forms of alprazolam are available in oral tablet strengths of 0.25mg, 0.5mg, 1mg, and 2mg and at significant lower costs of therapy. The rapidly dissolving dosage form is 4 times more expensive than the MAC'd oral generic product.

	<b>Drug</b>	<b>Dosage Form</b>	<b>Cost per Dosage Form</b>
<b>Program-specific information:</b>	• Niravam®	<i>0.25mg tab</i>	<i>\$1.2351AWP</i>
	• Niravam®	<i>0.5mg tab</i>	<i>\$1.5389 AWP</i>
	• Niravam®	<i>1mg tab</i>	<i>\$2.0533 AWP</i>
	• Niravam®	<i>2mg tab</i>	<i>\$3.4911 AWP</i>

**Setting & Population:** All patients.

**Type of  
Criteria:**

Increased risk of ADE

Non-Preferred Agent

Appropriate Indications

**Data Sources:**  Only administrative databases

Databases + Prescriber-supplied

## Setting & Population

- Drug for review: Niravam® (alprazolam oral disintegrating tablets)
- Age range: All ages
- Gender: Male and female

## Approval Criteria

Patient is unable to take generic tablet due to:

- Documented ADE/ADR to generic alprazolam tablets, or
- Trial and failure of alprazolam tablets in the past 45 days.

## Denial Criteria

- Failure to meet approval criteria.